Silk Road Medical, Inc Sustainability Profile
Silk Road Medical, Inc., a pioneering medical device company headquartered in the United States, focuses on innovative solutions for carotid artery disease. Founded in 2007, the company has made significant strides in the vascular intervention industry, particularly with its flagship product, the ENROUTE Transcarotid Neuroprotection System. This unique system enhances patient safety during carotid artery procedures, setting Silk Road Medical apart in a competitive market. With a strong presence in North America and expanding operations in Europe, Silk Road Medical has established itself as a leader in the field of neuroprotection and minimally invasive vascular interventions. The company’s commitment to advancing patient care is reflected in its notable achievements, including FDA approvals and recognition for its contributions to improving surgical outcomes.
DitchCarbon Score
How does Silk Road Medical, Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Silk Road Medical, Inc's score of 68 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Silk Road Medical, Inc's reported carbon emissions
In 2023, Silk Road Medical, Inc. reported total greenhouse gas emissions of approximately 205,000 kg CO2e for Scope 1 and about 587,900 kg CO2e for Scope 2, totalling around 792,900 kg CO2e globally. This data reflects a commitment to transparency in emissions reporting, although no Scope 3 emissions data has been disclosed. Comparatively, in 2022, the company recorded approximately 290,000 kg CO2e for Scope 1 and about 601,000 kg CO2e for Scope 2, resulting in a total of around 891,000 kg CO2e. This indicates a reduction in total emissions of about 98,100 kg CO2e from 2022 to 2023. Silk Road Medical, Inc. is a current subsidiary of Boston Scientific Corporation, which influences its climate commitments and reporting practices. However, there are currently no specific reduction targets or initiatives disclosed by Silk Road Medical, indicating a potential area for future development in their sustainability strategy. The absence of detailed climate pledges or SBTi targets suggests that the company may still be in the early stages of formalising its climate action commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 275,000 | 000,000 | 000,000 |
| Scope 2 | 525,500 | 000,000 | 000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Silk Road Medical, Inc's Industry?
How Carbon Intensive is Silk Road Medical, Inc's Location?
Silk Road Medical, Inc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Silk Road Medical, Inc has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Penumbra, Inc.
InspireMD, Inc.
Terumo Medical Corporation
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.